Jefferies has upgraded Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company focused on retinal (eye) diseases.

Fintel reports that on December 9, 2024, Jefferies upgraded their outlook for Kodiak Sciences (NasdaqGM:KOD) from Hold to Buy ...

Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from ...

Nona Biosciences announced a collaboration with Kodiak Sciences (KOD). This partnership aims to advance the discovery of ...

Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing ...

Shares of Kodiak Sciences (KOD) rallied 32% Monday after Jefferies upgraded the stock to buy from hold, citing the company’s turnaround and upcoming catalysts. Read more here.

On Monday, Jefferies analyst initiated an upgrade for shares of Kodiak Sciences Inc . (NASDAQ:KOD), shifting the stock's rating from Hold to Buy and significantly lifting the price target to $20. ...

Jefferies Financial Group upgraded shares of Kodiak Sciences (NASDAQ:KOD – Free Report) from a hold rating to a buy rating in a research report sent to investors on Monday morning, Marketbeat.com ...

Nona Biosciences and Kodiak Sciences Partner to Advance Multi-Target Antibody Discovery for Ophthalmic Diseases ...

Tarcocimab Phase 3 trials, GLOW2 and DAYBREAK, actively enrolling for retinal diseases. Kodiak stock could reach $20 or a $1 billion+ market cap, Jefferies notes. Jefferies has upgraded Kodiak ...